Anti-IL11RA Antibody (X209)
Based on 1 Customer Validation
Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003).
For research use only. We do not sell to patients.
- Purity : 97.75%
- Molecular Weight:145 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Anti-IL11RA Antibody (X209) (24 h) inhibits the secretion of profibrotic proteins by primary human hepatic stellate cells (HSCs), with an IC50 of 5.4 pM[1].
Anti-IL11RA Antibody (X209) (2 μg/mL; 24 h) inhibits the transformation of primary human hepatic stellate cells (HSCs) into myofibroblasts induced by various NASH-related stimuli[1].
Anti-IL11RA Antibody (X209) (2 μg/mL; 15 min pre-incubation, 48 h co-incubation) potently inhibits Matrigel invasion of primary human hepatic stellate cells (HSCs) induced by PDGF and CCL2[1].
Anti-IL11RA Antibody (X209) (24 h) potently inhibits the secretion of MMP2 and TIMP1 by mouse and human cardiac fibroblasts stimulated with TGFβ1, with an IC50 in the low nM range[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary human hepatic stellate cells (HSCs)
-
Concentration:2 μg/mL
-
Incubation Time:15 min (pre-incubation); 48 h (co-incubation with stimulus)
-
Result:Reduced PDGF/CCL2-induced HSC invasion compared to IgG-treated controls.
In Vivo
Anti-IL11RA Antibody (X209) (10 mg/kg; i.p.; three times weekly; 7 weeks) reduces liver fibrosis levels and inflammatory gene expression in mice with advanced non-alcoholic steatohepatitis (NASH) induced by Streptozotocin (HY-13753)[1].
Anti-IL11RA Antibody (X209) (20 mg/kg; i.p.; bi-weekly; 2 weeks) significantly attenuates AAC-induced cardiac fibrosis and ERK1/2 activation in male C57BL/6J mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6NTac (male, 5 weeks old, fed high fat methionine- and choline-deficient diet for 6 weeks to induce NASH)[1]
-
Dosage:10 mg/kg
-
Administration:s.c.; bi-weekly; 4 weeks
-
Result:Abolished hepatic ERK activation.
Reduced relative liver hydroxyproline.
Reduced serum ALT levels.
Did not alter hepatic steatosis.
Reduced mRNA expression of pro-fibrotic genes (Col1a1, Col1a2, Col3a1, Acta2, Timp1) and TGFβ1.
Increased Mmp2 mRNA expression.
-
Animal Model:C57BL/6J (male, 10-12 weeks old; cardiac fibrosis induced via ascending aortic constriction surgery)[2]
-
Dosage:20 mg/kg
-
Administration:i.p.; bi-weekly; 2 weeks
-
Result:Partially reduced AAC-induced cardiac IL11 protein expression.
Reduced AAC-induced extracellular matrix gene RNA expression, including Col1a1, Col1a2, Col3a1, Fn1, Mmp2, and Timp1.
Significantly reduced AAC-induced myocardial collagen I and III protein expression .
Significantly reduced total myocardial collagen and perivascular fibrosis.
Significantly reduced AAC-induced cardiac ERK1/2 phosphorylation.
Reduced indexed aortic root diameter, and showed significantly higher peak aortic velocity and pressure gradient.
Did not affect post-operative mortality, body weight recovery, terminal body weight, or AAC-induced cardiac hypertrophy.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of K562 cells labelling IL-11RA (red) with Anti-IL11RA Antibody (HY-P991219). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-IL11RA Antibody (X209)]
-
Synonyms
EnX209
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-IL11RA Antibody (X209) Related Classifications
HY-P991219 Related Classifications
Powered by Bioz